Patient should be human leukocyte antigen (HLA) typed (A, B, C, DR and DQ) during induction therapy phase or a written explanation for not undergoing HLA typing on the flow sheet
Any human leukocyte antigen (HLA) type; (historic HLA typing is permitted)
Human leukocyte antigen (HLA)-A1, A2, A3, B35, or B51.
No suitable human leukocyte antigen (HLA)-identical sibling donor
Donor and recipient match each other for at least 7/8 human leukocyte antigen (HLA)-loci (HLA-A, B, C, and D-related [DR]).
Lack human leukocyte antigen (HLA)-identical related donor
Patients must have one related donor who is human leukocyte antigen (HLA) mismatched in the GVHD direction at two or more HLA loci
Available human leukocyte antigen (HLA)-haploidentical donor that meets the criteria
Human leukocyte antigen (HLA)-A*0201 (HLA-A2.1) positivity by molecular subtyping
Human leukocyte antigen (HLA)-A*0201 (HLA-A2.1) positivity by molecular subtyping (blood test or buccal swab, historical documentation acceptable)
Patients must be human leukocyte antigen (HLA)-A2+
Human leukocyte antigen (HLA)-A2 positive based on flow cytometry
Absence anti-human leukocyte antigen (HLA) antibodies specific for HLA class I antigens expressed by the coagulation factor III (thromboplastin, tissue factor) (F3).cytosine deaminase (CD).carboxylesterase (CE) NSCs
Patients must be human leukocyte antigen (HLA)-DP4 positive
Patients must be human leukocyte antigen (HLA)-A*0201 positive
Leukocyte >= 3,000/ul
Human leukocyte antigen (HLA)-A*0201 (HLA-A2.1) positivity by molecular subtyping
Human leukocyte antigen (HLA)-A2 positive
Patients must have a related donor who is either human leukocyte antigen (HLA)-identical or a one antigen mismatch at the HLA- A; B; C; and DR loci
Patients must have human leukocyte antigen (HLA)-A2 phenotype
Human leukocyte antigen (HLA)-A1, -A2, -A3, or -A31 positive
Any human leukocyte antigen (HLA) type
Patient has anti-human leukocyte antigen (HLA) antibodies specific for HLA antigens expressed by the HB1.F3.CD NSCs
Patients must express human leukocyte antigen (HLA) -A1+, -A2+, or -A3+ (80% of patients)
DONOR: Human leukocyte antigen (HLA)-identical related donors or
DONOR: Human leukocyte antigen (HLA) identical to recipient subject
Human leukocyte antigen (HLA)-A*0201 (HLA-A2.1) positivity by molecular subtyping
Human leukocyte antigen (HLA)-A2 positive
Expression of human leukocyte antigen (HLA)-A:0201 or HLA-A:2402.
ELIGIBILITY FOR TREATMENT ON ARM 1: Patients must express human leukocyte antigen (HLA)-A*0201
Human leukocyte antigen (HLA)-A2-positive
Human leukocyte antigen HLA A2 positive
Expression of human leukocyte antigen (HLA)-A2
Patients must have one related donor who is human leukocyte antigen (HLA) mismatched in the GVHD direction at two or more HLA loci
Has a suitable human leukocyte antigen (HLA) haploidentical donor available
Human leukocyte antigen (HLA)-A2 positive by deoxyribonucleic acid (DNA) sequence analysis (by history or as part of this study); HLA testing can be done at local labs
Donor is blood-related and human leukocyte antigen (HLA)-haploidentical to the recipient
DONOR: Donors will be selected to minimize human leukocyte antigen (HLA) mismatch in the host-versus-graft direction
Patients must be human leukocyte antigen (HLA)-A*0201 positive
Available peptide-MHC pair that can be folded into a tetramer for which MCPyV TAg-specific cells can be generated and reactivity to cell lines expressing MCPyV TAg with the corresponding human leukocyte antigen (HLA)
Human leukocyte antigen (HLA)-A*02+ by serology by an ASHI accredited laboratory;
Leukocyte count <3000/µL,
Has a potentially suitable human leukocyte antigen (HLA) haploidentical donor available
Patients must be human leukocyte antigen (HLA) A2 positive by polymerase chain reaction (PCR) typing
Human leukocyte antigen (HLA) type A0201 or A2402
Patients must be human leukocyte antigen (HLA)-A*02:01-positive
Human leukocyte antigen (HLA)-A2 positive.
Any human leukocyte antigen (HLA) type (historic HLA typing is permitted)
Patients must be human leukocyte antigen (HLA)-A*0201 positive
Human leukocyte antigen (HLA)-A0201 or HLA-A2402
Availability of a willing and suitable human leukocyte antigen (HLA) identical related donor
Human leukocyte antigen (HLA)-identical sibling donor
Participants must be human leukocyte antigen (HLA)-A2 positive
Presence of human leukocyte antigen (HLA) antibodies
Availability of human leukocyte antigen (HLA)-identical sibling donor